drugset / Trial / NCT04856904

Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

NCT04856904

Phase 4 Completed 121 enrolled Galderma R&D
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and efficacy of trifarotene 50 microgram per gram (mcg/g) cream compared to its vehicle on the risk of formation of atrophic acne scars after 24 weeks of treatment in facial acne participants assessed by atrophic acne scars count.

Timeline

Start
2021-05-28
Primary completion
2023-02-08
Completion
2023-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Trifarotene Small molecule 50 unknown Topical

Indications